Drug Profile
Nivolumab companion diagnostic - Dako/ONO Pharmaceutical
Alternative Names: PD-L1 IHC 28-8 pharmDxLatest Information Update: 12 Apr 2022
Price :
$50
*
At a glance
- Originator Dako A/S; Ono Pharmaceutical
- Developer Agilent Technologies; Dako A/S; Ono Pharmaceutical
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
Most Recent Events
- 05 Apr 2022 Registered for Oesophageal cancer (Diagnosis, Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, Recurrent, Late-stage disease) in European Union (unspecified route)
- 05 Apr 2022 Registered for Urogenital cancer (Diagnosis, Adjuvant therapy) in European Union (unspecified route)
- 22 Oct 2021 Launched for Gastric cancer (Diagnosis) in USA (unspecified route) as of October 2021